Epigenetic therapies - A new direction in clinical medicine

International Journal of Clinical Practice

Volumn 68, Issue 7, 2014, Pages 802-811

  Stein, R A ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ASVASIRAN; AZACITIDINE; BEVASIRANIB; EPZ 005687; FR 235222; GSK 1210151A; GSK 126; HISTONE DEACETYLASE INHIBITOR; MIRAVIRSEN; MOCETINOSTAT; MS 147; MS 417; PROTEIN INHIBITOR; ROMIDEPSIN; RVX 208; SORAFENIB; UNCLASSIFIED DRUG; VORINOSTAT;

ATHEROSCLEROSIS; B CELL LYMPHOMA; CPG ISLAND; CUTANEOUS T CELL LEUKEMIA; CUTANEOUS T CELL LYMPHOMA; DIABETES MELLITUS; DIABETIC MACULAR EDEMA; DNA METHYLATION; DNA MODIFICATION; DRUG APPROVAL; EPIGENETICS; FOLLICULAR LYMPHOMA; FOOD AND DRUG ADMINISTRATION; GENE EXPRESSION; GENE SILENCING; GENE THERAPY; HEPATITIS C; HISTONE MODIFICATION; HIV ASSOCIATED NEPHROPATHY; HUMAN; LARGE CELL LYMPHOMA; LIVER CELL CARCINOMA; MYELODYSPLASTIC SYNDROME; NONHODGKIN LYMPHOMA; OVARY CANCER; PERIPHERAL T CELL LYMPHOMA; PRIORITY JOURNAL; PROTEIN PROCESSING; REVIEW; RNA INTERFERENCE; SUBRETINAL NEOVASCULARIZATION; T CELL LEUKEMIA; CLINICAL MEDICINE; GENETIC ENGINEERING; GENETIC EPIGENESIS; MEDICAL RESEARCH; PROCEDURES; TRENDS;

BIOMEDICAL RESEARCH; CLINICAL MEDICINE; EPIGENESIS, GENETIC; GENETIC ENGINEERING; HUMANS;

EID: 84902683042     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/ijcp.12436     Document Type: Review

References (169)

1. Hagelkruys A, Sawicka A, Rennmayr M, Seiser C,. The biology of HDAC in cancer: the nuclear and epigenetic components. Handb Exp Pharmacol 2011; 206: 13-37.
2. You JS, Jones PA,. Cancer genetics and epigenetics: two sides of the same coin? Cancer Cell 2012; 22 (1): 9-20.
3. Waldmann T, Schneider R,. Targeting histone modifications-epigenetics in cancer. Curr Opin Cell Biol 2013; 25 (2): 184-9.
4. Anand P, Kunnumakkara AB, Sundaram C, et al. Cancer is a preventable disease that requires major lifestyle changes. Pharm Res 2008; 25 (9): 2097-116.
5. Chuang JC, Jones PA,. Epigenetics and microRNAs. Pediatr Res 2007; 61 (5 Pt 2): 24R-9R.
6. Mulero-Navarro S, Esteller M,. Epigenetic biomarkers for human cancer: the time is now. Crit Rev Oncol Hematol 2008; 68 (1): 1-11.
7. Boumber Y, Issa JP,. Epigenetics in cancer: what's the future? Oncology (Williston Park) 2011; 25 (3): 220-6.
8. Yang X, Lay F, Han H, Jones PA,. Targeting DNA methylation for epigenetic therapy. Trends Pharmacol Sci 2010; 31 (11): 536-46.
9. Foulks JM, Parnell KM, Nix RN, et al. Epigenetic drug discovery: targeting DNA methyltransferases. J Biomol Screen 2012; 17 (1): 2.
10. Feinberg AP, Vogelstein B,. Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature 1983; 301 (5895): 89-92.
11. Pogribny IP, Pogribna M, Christman JK, James SJ,. Single-site methylation within the p53 promoter region reduces gene expression in a reporter gene construct: possible in vivo relevance during tumorigenesis. Cancer Res 2000; 60 (3): 588-94.
12. Daniel FI, Cherubini K, Yurgel LS, et al. The role of epigenetic transcription repression and DNA methyltransferases in cancer. Cancer 2011; 117 (4): 677-87.
13. Bird AP,. CpG-rich islands and the function of DNA methylation. Nature 1986; 321: 209-13.
14. Shen L, Kondo Y, Guo Y, et al. Genome-wide profiling of DNA methylation reveals a class of normally methylated CpG island promoters. PLoS Genet 2007; 3 (10): 2023-36.
15. Ghoshal K, Datta J, Majumder S, et al. 5-Aza-deoxycytidine induces selective degradation of DNA methyltransferase 1 by a proteasomal pathway that requires the KEN box, bromo-adjacent homology domain, and nuclear localization signal. Mol Cell Biol 2005; 25 (11): 4727-41.
16. Ghoshal K, Motiwala T, Claus R, et al. HOXB13, a target of DNMT3B, is methylated at an upstream CpG island, and functions as a tumor suppressor in primary colorectal tumors. PLoS ONE 2010; 5 (4): e10338.
17. Hansen KD, Timp W, Bravo HC, et al. Increased methylation variation in epigenetic domains across cancer types. Nat Genet 2011; 43 (8): 768-75.
18. Doi A, Park IH, Wen B, et al. Differential methylation of tissue- and cancer-specific CpG island shores distinguishes human induced pluripotent stem cells, embryonic stem cells and fibroblasts. Nat Genet 2009; 41: 1350-3.
19. Irizarry RA, Ladd-Acosta C, Wen B, et al. The human colon cancer methylome shows similar hypo- and hypermethylation at conserved tissue-specific CpG island shores. Nat Genet 2009; 41 (2): 178-86.
20. Rakyan VK, Down TA, Balding DJ, Beck S,. Epigenome-wide association studies for common human diseases. Nat Rev Genet 2011; 12 (8): 529-41.
21. Timp W, Feinberg AP,. Cancer as a dysregulated epigenome allowing cellular growth advantage at the expense of the host. Nat Rev Cancer 2013; 13 (7): 497-510.
22. Ghoshal K, Bai S,. DNA methyltransferases as targets for cancer therapy. Drugs Today (Barc) 2007; 43 (6): 395-422.
23. Kantarjian H, Issa JP, Rosenfeld CS, Bennett JM, Albitar M,. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a Phase III randomized study. Cancer 2006; 106: 1794-803.
24. Jain N, Rossi A, Garcia-Manero G,. Epigenetic therapy of leukemia: an update. Int J Biochem Cell Biol 2009; 41: 72-80.
25. Issa J-PJ, Kantarjian HM, Kirkpatrick P,. Azacitidine. Nature Rev Drug Discov 2005; 4: 275-6.
26. Kaminskas E, Farrell AT, Wang YC, Sridhara R, Pazdur R,. FDA drug approval summary: azacitidine (5-azacytidine, Vidaza) for injectable suspension. Oncologist 2005; 10 (3): 176-82.
27. Ganesan A, Nolan L, Crabb SJ, Packham G,. Epigenetic therapy: histone acetylation, DNA methylation and anti-cancer drug discovery. Curr Cancer Drug Targets 2009; 9: 963-81.
28. Silverman LR, Holland JF, Weinberg RS, et al. Effects of treatment with azacitidine on the in vivo and in vitro hematopoiesis in patients with myelodysplastic syndromes. Leukemia 1993; 7 (Suppl. 1): 21-9.
29. Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 2002; 20: 2429-40.
30. Gurion R, Vidal L, Gafter-Gvili A, et al. 5-azacitidine prolongs overall survival in patients with myelodysplastic syndrome-a systematic review and meta-analysis. Haematologica 2010; 95 (2): 303-10.
31. Azad N, Zahnow CA, Rudin CM, Baylin SB,. The future of epigenetic therapy in solid tumours-lessons from the past. Nat Rev Clin Oncol 2013; 10 (5): 256-66.
32. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009; 10 (3): 223-32.
33. Wijermans PW, Krulder JW, Huijgens PC, Neve P,. Continuous infusion of low-dose 5-Aza-2′-deoxycytidine in elderly patients with high-risk myelodysplastic syndrome. Leukemia 1997; 11: 1-5.
34. Wijermans P, Lubbert M, Verhoef G, et al. Low-dose 5-aza-2′- deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. J Clin Oncol 2000; 18: 956-62.
35. Gore SD, Jones C, Kirkpatrick P,. Decitabine. Nat Rev Drug Discov 2006; 5: 891-2.
36. Seidel C, Florean C, Schnekenburger M, Dicato M, Diederich M,. Chromatin-modifying agents in anti-cancer therapy. Biochimie 2012; 94: 2264-79.
37. Roopra A, Dingledine R, Hsieh J,. Epigenetics and epilepsy. Epilepsia 2012; 53 (Suppl. 9): 2-10.
38. Luger K, Mader AW, Richmond RK, et al. Crystal structure of the nucleosome core particle at 2.8 Å resolution. Nature 1997; 389: 251-60.
39. Andrews AJ, Luger K,. Nucleosome structure(s) and stability: variations on a theme. Annu Rev Biophys 2011; 40: 99-117.
40. Popovic R, Shah MY, Licht JD,. Epigenetic therapy of hematological malignancies: where are we now? Ther Adv Hematol 2013; 4: 81-91.
41. Bernstein BE, Mikkelsen TS, Xie X, et al. A bivalent chromatin structure marks key developmental genes in embryonic stem cells. Cell 2006; 125: 315-26.
42. Strahl BD, Allis CD,. The language of covalent histone modifications. Nature 2000; 403: 41-5.
43. Jenuwein T, Allis CD,. Translating the histone code. Science 2001; 293: 1074-80.
44. Ruthenburg AJ, Li H, Patel DJ, Allis CD,. Multivalent engagement of chromatin modifications by linked binding modules. Nat Rev Mol Cell Biol 2007; 8: 983-94.
45. Mercurio C, Minucci S, Pelicci PG,. Histone deacetylases and epigenetic therapies of hematological malignancies. Pharmacol Res 2010; 62: 18-34.
46. Miller CP, Singh MM, Rivera-Del Valle N, et al. Therapeutic strategies to enhance the anticancer efficacy of histone deacetylase inhibitors. J Biomed Biotechnol 2011; 2011: 514261.
47. Filippakopoulos P, Picaud S, Mangos M, et al. Histone recognition and large-scale structural analysis of the human bromodomain family. Cell 2012; 149: 214-31.
48. Gu W, Roeder RG,. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell 1997; 90: 595-606.
49. Brooks CL, Gu W,. Ubiquitination, phosphorylation and acetylation: the molecular basis for p53 regulation. Curr Opin Cell Biol 2003; 15: 164-71.
50. Luo J, Su F, Chen D, Shiloh A, Gu W,. Deacetylation of p53 modulates its effect on cell growth and apoptosis. Nature 2000; 408: 377-81.
51. Marzio G, Wagener C, Gutierrez MI, Cartwright P, Helin K, Giacca M,. E2F family members are differentially regulated by reversible acetylation. J Biol Chem 2000; 275: 10887-92.
52. Bereshchenko OR, Gu W, Dalla-Favera R,. Acetylation inactivates the transcriptional repressor BCL6. Nat Genet 2002; 32: 606-13.
53. Ververis K, Karagiannis TC,. Potential non-oncological applications of histone deacetylase inhibitors. Am J Transl Res 2011; 3: 454-67.
54. Lemoine M, Younes A,. Histone deacetylase inhibitors in the treatment of lymphoma. Discov Med 2010; 10: 462-70.
55. Duvic M, Talpur R, Ni X, et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 2007; 109: 31-9.
56. Olsen EA, Kim YH, Kuzel TM, et al. Phase IIB multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol 2007; 25: 3109-15.
57. Duvic M, Vu J,. Update on the treatment of cutaneous T-cell lymphoma (CTCL): focus on vorinostat. Biologics 2007; 1: 377-92.
58. Mann BS, Johnson JR, Cohen MH, Justice R, Pazdur R,. FDA approval summary: Vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist 2007; 12: 1247-52.
59. Khan O, La Thangue NB,. HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications. Immunol Cell Biol 2012; 90: 85-94.
60. VanderMolen KM, McCulloch W, Pearce CJ, Oberlies NH,. Romidepsin (Istodax, NSC 630176, FR901228, FK228, depsipeptide): a natural product recently approved for cutaneous T-cell lymphoma. J Antibiot (Tokyo) 2011; 64: 525-31.
61. Prince HM, Bishton MJ, Harrison SJ,. Clinical studies of histone deacetylase inhibitors. Clin Cancer Res 2009; 15: 3958-69.
62. Piekarz RL, Frye R, Turner M, et al. Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol 2009; 27: 5410-7.
63. Whittaker SJ, Demierre MF, Kim EJ, et al. Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. J Clin Oncol 2010; 28: 4485-91.
64. Piekarz RL, Frye R, Prince HM, et al. Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. Blood 2011; 117: 5827-34.
65. Simon JA, Lange CA,. Roles of the EZH2 histone methyltransferase in cancer epigenetics. Mutat Res 2008; 647: 21-9.
66. Morey L, Helin K,. Polycomb group protein-mediated repression of transcription. Trends Biochem Sci 2010; 35: 323-32.
67. Chase A, Cross NC,. Aberrations of EZH2 in cancer. Clin Cancer Res 2011; 17: 2613-8.
68. Xiao Y,. Enhancer of zeste homolog 2: a potential target for tumor therapy. Int J Biochem Cell Biol 2011; 43: 474-7.
69. Knutson SK, Wigle TJ, Warholic NM, et al. A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells. Nat Chem Biol 2012; 8: 890-6.
70. McCabe MT, Ott HM, Ganji G, et al. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature 2012; 492: 108-12.
71. Chi P, Allis CD, Wang GG,. Covalent histone modifications-miswritten, misinterpreted and mis-erased in human cancers. Nat Rev Cancer 2010; 10: 457-69.
72. Upadhyay AK, Cheng X,. Dynamics of histone lysine methylation: structures of methyl writers and erasers. Prog Drug Res 2011; 67: 107-24.
73. Arrowsmith CH, Bountra C, Fish PV, Lee K, Schapira M,. Epigenetic protein families: a new frontier for drug discovery. Nat Rev Drug Discov 2012; 11: 384-400.
74. Belkina AC, Denis GV,. BET domain co-regulators in obesity, inflammation and cancer. Nat Rev Cancer 2012; 12: 465-77.
75. Haynes SR, et al. The bromodomain: a conserved sequence found in human, Drosophila and yeast proteins. Nucl Acids Res 1992; 20: 2603.
76. Wu SY, Chiang CM,. The double bromodomain-containing chromatin adaptor Brd4 and transcriptional regulation. J Biol Chem 2007; 282: 13141-5.
77. Vidler LR, Brown N, Knapp S, Hoelder S,. Druggability analysis and structural classification of bromodomain acetyl-lysine binding sites. J Med Chem 2012; 55: 7346-59.
78. Andreol F, Barbosa AJ, Parenti MD, Del Rio A,. Modulation of Epigenetic Targets for Anticancer Therapy: clinicopathological Relevance, Structural Data and Drug Discovery Perspectives. Curr Pharm Des 2013; 19: 578-613.
79. Sanchez R, Zhou MM,. The role of human bromodomains in chromatin biology and gene transcription. Curr Opin Drug Discov Devel 2009; 12: 659-65.
80. Seal J, Lamotte Y, Donche F, et al. Identification of a novel series of BET family bromodomain inhibitors: binding mode and profile of I-BET151 (GSK1210151A). Bioorg Med Chem Lett 2012; 22: 2968-72.
81. Nicodeme E, Jeffrey KL, Schaefer U, et al. Suppression of inflammation by a synthetic histone mimic. Nature 2010; 468: 1119-23.
82. Delmore JE, Issa GC, Lemieux ME, et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 2011; 146: 904-17.
83. Mertz JA, Conery AR, Bryant BM, et al. Targeting MYC dependence in cancer by inhibiting BET bromodomains. Proc Natl Acad Sci USA 2011; 108: 16669-74.
84. Anand P, Brown JD, Lin CY, et al. BET Bromodomains Mediate Transcriptional Pause Release in Heart Failure. Cell 2013; 154: 569-82.
85. Zhang G, Liu R, Zhong Y, et al. Down-regulation of NF-kappaB transcriptional activity in HIV-associated kidney disease by BRD4 inhibition. J Biol Chem 2012; 287: 28840-51.
86. Barbieri M,. Biosemiotic Research Trends. New York: Nova Science Pub Inc, 2007. ISBN-13: 978-1600215742. 2007.
87. International Human Genome Sequencing Consortium. Initial sequencing and analysis of the human genome. Nature 2001; 409: 860-921.
88. Gregory TR,. Synergy between sequence and size in large-scale genomics. Nat Rev Genet 2005; 6: 699-708.
89. Eory L, Halligan DL, Keightley PD,. Distributions of selectively constrained sites and deleterious mutation rates in the hominid and murid genomes. Mol Biol Evol 2010; 27: 177-92.
90. Fiorucci G, Chiantore MV, Mangino G, Percario ZA, Affabris E, Romeo G,. Cancer regulator microRNA: potential relevance in diagnosis, prognosis and treatment of cancer. Curr Med Chem 2012; 19: 461-74.
91. Ko YA, Susztak K,. Epigenomics: the science of no-longer-junk DNA. Why study it in chronic kidney disease? Semin Nephrol 2013; 33 (4): 354-62.
92. Zaratiegui M, Irvine DV, Martienssen RA,. Noncoding RNAs and gene silencing. Cell 2007; 128: 763-76.
93. Pandey R, Mukerji M,. From 'JUNK' to just unexplored noncoding knowledge: the case of transcribed Alus. Brief Funct Genomics 2011; 10: 294-311.
94. Filipowicz W, Bhattacharyya SN, Sonenberg N. Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? Nat Rev Genet 2008; 9: 102-14.
95. Kusenda B, Mraz M, Mayer J, Pospisilova S,. MicroRNA biogenesis, functionality and cancer relevance. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2006; 150: 205-15.
96. Filipowicz W, Jaskiewicz L, Kolb FA, Pillai RS,. Post-transcriptional gene silencing by siRNAs and miRNAs. Curr Opin Struct Biol 2005; 15: 331-41.
97. Rana TM,. Illuminating the silence: understanding the structure and function of small RNAs. Nat Rev Mol Cell Biol 2007; 8: 23-36.
98. Fabian MR, Sonenberg N,. The mechanics of miRNA-mediated gene silencing: a look under the hood of miRISC. Nat Struct Mol Biol 2012; 19: 586-93.
99. Hammond SM, Caudy AA, Hannon GJ,. Post-transcriptional gene silencing by double-stranded RNA. Nat Rev Genet 2001; 2: 110-9.
100. Murashov AK,. A brief introduction to RNAi and microRNAs in stem cells. Methods Mol Biol 2010; 650: 15-25.
101. Phalon C, Rao DD, Nemunaitis J,. Potential use of RNA interference in cancer therapy. Expert Rev Mol Med 2010; 18: e26.
102. Esau CC, Monia BP,. Therapeutic potential for microRNAs. Adv Drug Deliv Rev 2007; 59: 101-14.
103. Medina PP, Nolde M, Slack FJ,. OncomiR addiction in an in vivo model of microRNA-21-induced pre-B-cell lymphoma. Nature 2010; 467: 86-90.
104. Weinstein IB, Joe A,. Oncogene addiction. Cancer Res 2008; 68: 3077-80.
105. Kulshreshtha R, Ferracin M, Wojcik SE, et al. A microRNA signature of hypoxia. Mol Cell Biol 2007; 27: 1859-67.
106. Teicher BA,. Hypoxia and drug resistance. Cancer Metastasis Rev 1994; 13: 139-68.
107. Kulshreshtha R, Davuluri RV, Calin GA, Ivan M,. A microRNA component of the hypoxic response. Cell Death Differ 2008; 15: 667-71.
108. Hu S, Huang M, Li Z, et al. MicroRNA-210 as a novel therapy for treatment of ischemic heart disease. Circulation 2010; 122 (11 Suppl): S124-31.
109. Trang P, Wiggins JF, Daige CL, et al. Systemic delivery of tumor suppressor microRNA mimics using a neutral lipid emulsion inhibits lung tumors in mice. Mol Ther 2011; 19 (6): 1116-22.
110. Wang Z,. The concept of multiple-target anti-miRNA antisense oligonucleotide technology. Methods Mol Biol 2011; 676: 51-7.
111. Hullinger TG, Montgomery RL, Seto AG, et al. Inhibition of miR-15 Protects Against Cardiac Ischemic Injury. Circ Res 2012; 110 (1): 71-81.
112. Rayner KJ, Esau CC, Hussain FN, et al. Inhibition of miR-33a/b in non-human primates raises plasma HDL and lowers VLDL triglycerides. Nature 2011; 478 (7369): 404-7.
113. Aleku M, Schulz P, Keil O, et al. Atu027, a liposomal small interfering RNA formulation targeting protein kinase N3, inhibits cancer progression. Cancer Res 2008; 68 (23): 9788-98.
114. Santel A, Aleku M, Röder N, et al. Atu027 prevents pulmonary metastasis in experimental and spontaneous mouse metastasis models. Clin Cancer Res 2010; 16 (22): 5469-80.
115. Strumberg D, Schultheis B, Traugott U, et al. Phase I clinical development of Atu027, a siRNA formulation targeting PKN3 in patients with advanced solid tumors. Int J Clin Pharmacol Ther 2012; 50 (1): 76-8.
116. Tabernero J, Shapiro GI, LoRusso PM, et al. First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement. Cancer Discov 2013; 3 (4): 406-17.
117. Nguyen QD, Schachar RA, Nduaka CI, et al. Dose-ranging evaluation of intravitreal siRNA PF-04523655 for diabetic macular edema (the DEGAS study). Invest Ophthalmol Vis Sci 2012; 53 (12): 7666-74.
118. Ho AS, Turcan S, Chan TA,. Epigenetic therapy: use of agents targeting deacetylation and methylation in cancer management. Onco Targets Ther 2013; 6: 223-32.
119. Hasan A, Mitchell A, Schneider A, Halene T, Akbarian S,. Epigenetic dysregulation in schizophrenia: molecular and clinical aspects of histone deacetylase inhibitors. Eur Arch Psychiatry Clin Neurosci 2013; 263 (4): 273-84.
120. Fass DM, Schroeder FA, Perlis RH, Haggarty SJ,. Epigenetic mechanisms in mood disorders: targeting neuroplasticity. Neuroscience 2014; 264C: 112-30.
121. Wang Y, Fan PS, Kahaleh B,. Association between enhanced type I collagen expression and epigenetic repression of the FLI1 gene in scleroderma fibroblasts. Arthritis Rheum 2006; 54 (7): 2271-9.
122. Gray SG,. Targeting histone deacetylases for the treatment of Huntington's disease. CNS Neurosci Ther 2010; 16 (6): 348-61.
123. Chen S, Wu H, Ossola B, et al. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, protects dopaminergic neurons from neurotoxin-induced damage. Br J Pharmacol 2012; 165 (2): 494-505.
124. Hancock WW, Akimova T, Beier UH, Liu Y, Wang L,. HDAC inhibitor therapy in autoimmunity and transplantation. Ann Rheum Dis 2012; 71 (Suppl. 2): i46-54.
125. Kong S, Yeung P, Fang D,. The class III histone deacetylase sirtuin 1 in immune suppression and its therapeutic potential in rheumatoid arthritis. J Genet Genomics 2013; 40 (7): 347-54.
126. Chittur SV, Sangster-Guity N, McCormick PJ,. Histone deacetylase inhibitors: a new mode for inhibition of cholesterol metabolism. BMC Genomics 2008; 9: 507.
127. Nunes MJ, Moutinho M, Gama MJ, Rodrigues CM, Rodrigues E,. Histone deacetylase inhibition decreases cholesterol levels in neuronal cells by modulating key genes in cholesterol synthesis, uptake and efflux. PLoS ONE 2013; 8 (1): e53394.
128. Singerman L,. Combination therapy using the small interfering RNA bevasiranib. Retina 2009; 29 (6 Suppl): S49-50.
129. Mousa SA, Mousa SS,. Current status of vascular endothelial growth factor inhibition in age-related macular degeneration. BioDrugs 2010; 24 (3): 183-94.
130. Bougdour A, Maubon D, Baldacci P, et al. Drug inhibition of HDAC3 and epigenetic control of differentiation in Apicomplexa parasites. J Exp Med 2009; 206 (4): 953-66.
131. Zamora MR, Budev M, Rolfe M, et al. RNA interference therapy in lung transplant patients infected with respiratory syncytial virus. Am J Respir Crit Care Med 2011; 183 (4): 531-8.
132. Wightman F, Ellenberg P, Churchill M, Lewin SR,. HDAC inhibitors in HIV. Immunol Cell Biol 2012; 90 (1): 47-54.
133. Janssen HL, Reesink HW, Lawitz EJ, et al. Treatment of HCV infection by targeting microRNA. N Engl J Med 2013; 368 (18): 1685-94.
134. Menke A, Klengel T, Binder EB,. Epigenetics, depression and antidepressant treatment. Curr Pharm Des 2012; 18 (36): 5879-89.
135. Nishioka M, Bundo M, Kasai K, Iwamoto K,. DNA methylation in schizophrenia: progress and challenges of epigenetic studies. Genome Med 2012; 4 (12): 96.
136. Schroeder FA, Lewis MC, Fass DM, et al. A selective HDAC 1/2 inhibitor modulates chromatin and gene expression in brain and alters mouse behavior in two mood-related tests. PLoS ONE 2013; 8 (8): e71323.
137. Nishioka M, Bundo M, Koike S, et al. Comprehensive DNA methylation analysis of peripheral blood cells derived from patients with first-episode schizophrenia. J Hum Genet 2013; 58 (2): 91-7.
138. Renthal W, Nestler EJ,. Epigenetic mechanisms in drug addiction. Trends Mol Med 2008; 14 (8): 341-50.
139. Lujambio A, Calin GA, Villanueva A, et al. A microRNA DNA methylation signature for human cancer metastasis. Proc Natl Acad Sci USA 2008; 105 (36): 13556-61.
140. Kitago M, Martinez SR, Nakamura T, Sim MS, Hoon DS,. Regulation of RUNX3 tumor suppressor gene expression in cutaneous melanoma. Clin Cancer Res 2009; 15 (9): 2988-94.
141. Smiraglia DJ, Smith LT, Lang JC, et al. Differential targets of CpG island hypermethylation in primary and metastatic head and neck squamous cell carcinoma (HNSCC). J Med Genet 2003; 40 (1): 25-33.
142. Cavalli LR, Urban CA, Dai D, et al. Genetic and epigenetic alterations in sentinel lymph nodes metastatic lesions compared to their corresponding primary breast tumors. Cancer Genet Cytogenet 2003; 146 (1): 33-40.
143. Barekati Z, Radpour R, Lu Q, et al. Methylation signature of lymph node metastases in breast cancer patients. BMC Cancer 2012; 12: 244.
144. Messick CA, Church JM, Liu X, Ting AH, Kalady MF,. Stage III colorectal cancer: molecular disparity between primary cancers and lymph node metastases. Ann Surg Oncol 2010; 17 (2): 425-31.
145. Han H, Wolff EM, Liang G,. Epigenetic alterations in bladder cancer and their potential clinical implications. Adv Urol 2012; 2012: 546917.
146. Feinberg AP, Ohlsson R, Henikoff S,. The epigenetic progenitor origin of human cancer. Nat Rev Genet 2006; 7 (1): 21-33.
147. Toyota M, Issa JP,. Epigenetic changes in solid and hematopoietic tumors. Semin Oncol 2005; 32 (5): 521-30.
148. Oyama T, Yamada Y, Hata K, et al. Further upregulation of beta-catenin/Tcf transcription is involved in the development of macroscopic tumors in the colon of ApcMin/+ mice. Carcinogenesis 2008; 29 (3): 666-72.
149. Eads CA, Lord RV, Kurumboor SK, et al. Fields of aberrant CpG island hypermethylation in Barrett's esophagus and associated adenocarcinoma. Cancer Res 2000; 60 (18): 5021-6.
150. Palmisano WA, Divine KK, Saccomanno G, et al. Predicting lung cancer by detecting aberrant promoter methylation in sputum. Cancer Res 2000; 60: 5954-8.
151. Lund G, Andersson L, Lauria M, et al. DNA methylation polymorphisms precede any histological sign of atherosclerosis in mice lacking apolipoprotein E. J Biol Chem 2004; 279 (28): 29147-54.
152. Baccarelli A, Rienstra M, Benjamin EJ,. Cardiovascular epigenetics: basic concepts and results from animal and human studies. Circ Cardiovasc Genet 2010; 3 (6): 567-73.
153. Yan PS, Venkataramu C, Ibrahim A, et al. Mapping geographic zones of cancer risk with epigenetic biomarkers in normal breast tissue. Clin Cancer Res 2006; 12: 6626-36.
154. Shen J, Stass SA, Jiang F,. MicroRNAs as potential biomarkers in human solid tumors. Cancer Lett 2013; 329 (2): 125-36.
155. Ma Y, Wang X, Jin H,. Methylated DNA and microRNA in Body Fluids as Biomarkers for Cancer Detection. Int J Mol Sci 2013; 14 (5): 10307-31.
156. Dietrich D, Kneip C, Raji O, et al. Performance evaluation of the DNA methylation biomarker SHOX2 for the aid in diagnosis of lung cancer based on the analysis of bronchial aspirates. Int J Oncol 2012; 40 (3): 825-32.
157. Church TR, Wandell M, Lofton-Day C, et al. Prospective evaluation of methylated SEPT9 in plasma for detection of asymptomatic colorectal cancer. Gut 2014; 63 (2): 317-25.
158. Tóth K, Sipos F, Kalmár A, et al. Detection of methylated SEPT9 in plasma is a reliable screening method for both left- and right-sided colon cancers. PLoS ONE 2012; 7 (9): e46000.
159. Bitzer M, Horger M, Ganten T, et al. Investigation of the HDAC inhibitor resminostat in patients with sorafenib-resistant hepatocellular carcinoma (HCC): clinical data from the Phase I/II SHELTER Study. Poster presented at the 19-21 January, 2012 Gastrointestinal Cancer Symposium (ASCO, ASTRO, SSO), San Francisco, CA.
160. Fu S, Hu W, Iyer R, et al. Phase 1b-2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer. Cancer 2011; 117 (8): 1661-9.
161. Jia G, Fu Y, Zhao X, et al. N6-methyladenosine in nuclear RNA is a major substrate of the obesity-associated FTO. Nat Chem Biol 2011; 7 (12): 885-7.
162. Zheng G, Dahl JA, Niu Y, et al. ALKBH5 is a mammalian RNA demethylase that impacts RNA metabolism and mouse fertility. Mol Cell 2013; 49 (1): 18-29.
163. Zheng G, Dahl JA, Niu Y, et al. Sprouts of RNA epigenetics: the discovery of mammalian RNA demethylases. RNA Biol 2013; 10 (6): 915-8.
164. Best JD, Carey N,. Epigenetic opportunities and challenges in cancer. Drug Discov Today 2010; 15 (1-2): 65-70.
165. Tuma RS,. Targeted epigenetic therapies: the next frontier? J Natl Cancer Inst 2010; 102 (24): 1824-5.
166. Rius M, Lyko F,. Epigenetic cancer therapy: rationales, targets and drugs. Oncogene 2012; 31 (39): 4257-65.
167. Hatzimichael E, Crook T,. Cancer epigenetics: new therapies and new challenges. J Drug Deliv 2013; 2013: 529312.
168. Arrowsmith CH, Bountra C, Fish PV, Lee K, Schapira M,. Epigenetic protein families: a new frontier for drug discovery. Nat Rev Drug Discov 2012; 11 (5): 384-400.
169. DeWoskin VA, Million RP,. The epigenetics pipeline. Nat Rev Drug Discov 2013; 12 (9): 661-2.